Association of Continued Use of SGLT2 Inhibitors From the Ambulatory to Inpatient Setting With Hospital Outcomes in Patients With Diabetes: A Nationwide Cohort Study
Main finding · In-hospital mortalityResult — go to the resultIncidence rate ratio 0.55 95% CI 0.42–0.73Authors' conclusion
Continued SGLT2i during hospitalization among patients with diabetes was associated with lower mortality, no increased AKI, and shorter LOS.
Study context
- Population
- Admissions of patients with diabetes with an outpatient SGLT2i prescription before acute care hospitalization, Veterans Affairs health care system, 1 April 2013–31 August 2021
- Participants
- 36,505 admissions
- Exposure
- SGLT2i continued vs discontinued during hospitalization
- Outcome
- In-hospital mortality
Methodological detailsnationwide, propensity score-weighted, negative binomial and zero-truncated analyses
- Nationwide
- Propensity score-weighted
- Negative binomial and zero-truncated analyses
Main finding
As reported in the abstract
Incidence rate ratio
0.55
95% CI 0.42–0.73
P < 0.01
SGLT2i continuedvs SGLT2i discontinued
IRR 0.55 (95% CI 0.42–0.73); P < 0.01
Observational data: associations, not effects.
Secondary outcomes
Days
| Outcome | SGLT2i continued | SGLT2i discontinued | IRR (95% CI) | P value | |
|---|---|---|---|---|---|
| AKI | 0.96 (0.90–1.02) | P = 0.17 | |||
| LOS | 4.7 | 4.9 | 0.95 (0.93–0.98) | P < 0.01 | |
| 0.512Incidence rate ratio (log scale) |
Sensitivity analyses
- Similar associations across multiple sensitivity analyses
Original publication
Association of Continued Use of SGLT2 Inhibitors From the Ambulatory to Inpatient Setting With Hospital Outcomes in Patients With Diabetes: A Nationwide Cohort Study. Diabetes Care. Published 5 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →